Profile image
By ETF Daily News (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Eli Lilly Shares Tank 15% As Alzheimer Drug Fails Clinical Trial

Wednesday, November 23, 2016 5:33
% of readers think this story is Fact. Add your two cents.

Drug making giant Eli Lilly and Co (NYSE:LLY) saw its shares plunge up to 15% in early trading Wednesday, after news broke that its key Alzheimer’s treatment failed its latest clinical trial.

The Indianapolis-based company said that solanezumab did not meet the primary endpoint in the EXPEDITION3 trial. The drug was being tested for its effectiveness in the treatment of mild dementia due to Alzheimer’s disease.

Lilly noted patients treated with solanezumab “did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo (p=.095), as measured by the ADAS-Cog14 (Alzheimer’s Disease Assessment Scale-Cognitive subscale).”

While solanezumab showed some promise in the study results, the size of the drug’s effects were small. LLY also announced that there were no new safety signals found in the study.

As a result of the failed trial, the company will not attempt to receive regulatory approval for the drug for the treatment of mild dementia due to Alzheimer’s disease. The debacle is expected to a cost LLY a fourth quarter pre-tax charge of about $150 million, or around $0.09 per share on an after-tax basis.

Next month, December 15, Lilly will update its 2016 financial guidance and announce its 2017 financial forecast. Investors will get a good idea of just how badly this drug failure will impact results then.

Eli Lilly shares fell $10.79 (-14.20%) to $65.20 in premarket trading Wednesday. Prior to today’s news, LLY had already plunged -9.81% year-to-date, versus an +8.19% rise in the benchmark S&P 500 index during the same period.


You are viewing an abbreviated republication of ETF Daily News content. You can find full ETF Daily News articles on (


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.